In 2012 the ACS, USPSTF and ACOG released updated recommendations for cervical cancer screening, and the ASCCP issued revisions of the earlier guidelines for management of abnormal Pap smears. The following incorporates these recommendations and guidelines. Visible lesions of the cervix require biopsy regardless of cytology results.
AGC and AIS
Endometrial Cells, Stromal Cells or Histiocytes on Cervical Cytology
Management of the postmenopausal woman with abnormal cervical cytology in general follows the same guidelines as for the premenopausal woman. Any abnormality, including ASC-US should be factored into the equation when deciding on when to stop performing Pap smears. Per USPSTF recommendations: “Women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion or cervical cancer are not at risk for cervical cancer and should not be screened. As part of the clinical evaluation, clinicians should confirm through review of surgical records or direct examination that the cervix was removed.”
Please log in to ObGFirst to access this page